Henry Meds vs MyStart Health

Choose Henry Meds if: You need tirzepatide access for superior weight loss efficacy (15-22% vs semaglutide 10-15%), experienced suboptimal semaglutide response requiring alternative medications, prioritize platform maturity and operational stability for long-term treatment continuity, value established track record (2+ years) and proven medication supply reliability, or accept $360/year premium ($247-297/month vs $217-267/month) for dual-medication formulary and greater platform credibility.

Choose MyStart Health if: You exclusively prioritize minimal costs saving $360/year ($217-267/month for semaglutide only), respond adequately to semaglutide without needing tirzepatide superior efficacy, accept startup platform risks regarding long-term viability and supply consistency, don't require complete medication formulary or treatment flexibility, or make purchasing decisions based primarily on lowest pricing rather than operational maturity.

Bottom line: Henry Meds and MyStart Health both provide budget-conscious compound semaglutide GLP-1 weight loss treatment with comparable basic consultation quality but differ in medication formulary, operational maturity, and pricing. Henry Meds ($247-297/month semaglutide, $347-397/month tirzepatide) offers superior medication access, established 2+ year track record, proven supply reliability, and dual-formulary flexibility justifying $360/year premium over MyStart. MyStart Health ($217-267/month semaglutide-only) delivers lowest pricing through emerging startup positioning but sacrifices tirzepatide access, operational stability, and long-term viability confidence. For patients needing maximum efficacy or multi-year treatment reliability, Henry Meds justifies premium. For extreme budget-consciousness accepting semaglutide-only limitation and startup risks, MyStart provides $360 annual savings. Tirzepatide access alone may justify Henry Meds premium for patients requiring superior weight loss outcomes.